Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week

Published in Urology and

Journal Scan / Research · September 17, 2020

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin vs Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Muscle-Invasive Bladder Cancer

European Urology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Gautam Jayram MD

Guru Sonpavde MD

European Urology

Randomized Phase III Trial of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-Invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

Eur Urol 2020 Aug 28;[EPub Ahead of Print], C Pfister, G Gravis, A Fléchon, M Soulié, L Guy, B Laguerre, N Mottet, F Joly, Y Allory, V Harter, S Culine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Bladder Cancer

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin vs Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Muscle-Invasive Bladder Cancer

Additional Info

Further Reading

Contribution of Gleason Pattern 4 Prostate Tissue to Blood PSA Levels

The Impact of Local Staging of Prostate Cancer Determined on MRI or DRE at Time of Radical Prostatectomy on Progression-Free Survival

Treatment Decision Regret in Long-Term Prostate Cancer Survivors After Radical Prostatectomy

Systemic Inflammation Response Index as an Independent Predictive Factor for Survival Outcomes in Patients With Bladder Cancer

Multiple Recurrences and Disease Progression in Patients With Intermediate-Risk NMIBC

Intracavernosal Injection of Botulinum Toxin in the Treatment of Erectile Dysfunction

Median 5-Year Outcomes of Primary Focal IRE for Localised Prostate Cancer

Log Odds of Positive Lymph Nodes as an Independent Predictor of Overall Survival After Radical Cystectomy in Patients With Urothelial Bladder Cancer

Shifting Risk-Stratified Early Prostate Cancer Detection to a Primary Healthcare Setting

Relationship Between the Number of Lymph Nodes Dissected and Prognosis in Patients With MIBC in the Era of Neoadjuvant Chemotherapy

Novel Potential Risk Factors for Postoperative Complications Following Primary Hypospadias Repair

Recently Updated